Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of RSV Vaccine VN-0200 in Healthy Japanese Adults and Elderly
NCT04914520Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2021
- Primary completion
- Dec 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VAGA-9001a + MABH-9002b in respiratory syncytial virus infection (RSV) (8 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Number of Participants Reporting Treatment-emergent Adverse Events, Number of Participants Reporting Local and Systemic Adverse Events and 1 more. Started Jun 2021; status: completed.
02
Drugs
VAGA-9001a + MABH-9002b
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04914520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04914520.